Silence Therapeutics plc (NASDAQ:SLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $33.83.

Several analysts have issued reports on the stock. Morgan Stanley decreased their price objective on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday, March 7th. BMO Capital Markets reduced their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group reduced their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a research report on Friday. Finally, Chardan Capital reduced their target price on shares of Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics during the fourth quarter worth about $26,000. GAMMA Investing LLC grew its stake in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after acquiring an additional 5,233 shares in the last quarter. Barclays PLC grew its stake in Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after acquiring an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Silence Therapeutics during the 4th quarter valued at about $69,000. Finally, Virtus ETF Advisers LLC grew its stake in Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after acquiring an additional 6,098 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $3.83 on Tuesday. Silence Therapeutics has a 52-week low of $1.97 and a 52-week high of $24.38. The firm has a market capitalization of $114.63 million, a PE ratio of -2.44 and a beta of 1.20. The stock has a fifty day simple moving average of $3.37 and a two-hundred day simple moving average of $6.31.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. The company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. On average, sell-side analysts forecast that Silence Therapeutics will post -1.77 EPS for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.